Disseminated on Behalf of: Algernon Pharmaceuticals
- Algernon sold its Ifenprodil research program in Q2 of this year to U.S. based Seyltx, Inc. for US$2 million and a 20% common share equity position
- Sub-psychedelic DMT has been shown to promote brain healing neuroplasticity both in vitro and in vivo, and is now Algernon’s primary research focus
- Addressable global markets for stroke and traumatic brain injury (TBI) therapies are projected to grow to US$15 billion by 2027 and US$4.5 billion by 2026, respectively
From Mind-Bending to Mind-Mending
Every hour of every day, in hospitals around the world, devastated family members keep vigil in waiting rooms and at bedsides, hoping and praying that the stroke their loved one just had does not leave them with catastrophic physical and/or cognitive disabilities, or take their life.
A stroke occurs when the blood supply to a part of the brain is interrupted — either through a blockage (ischemic stroke) or an uncontrolled bleed (hemorrhagic stroke) shutting down the delivery of oxygen and nutrients that can result in paralysis, speech/language problems, thinking and memory issues, and other forms of potentially permanent functional impairment. A TBI occurs as a result of an external force to the head caused by falls, vehicular accidents, sports injuries, assaults, combat injuries, and other impacts.
For strokes, depending upon the type and severity, how fast a patient gets to the emergency room, the kind of medical centre receiving the patient, CT or MRI imaging availability and diagnosis, the therapeutic window, and candidate criteria for procedures, the vast majority of patients are unable or ineligible to receive the most effective intervention therapies available to help stop, reverse, and reduce any potential loss of function.
These therapies could include tPAs (Tissue Plasminogen Activator) to break up clots, blood thinners, a thrombectomy to physically remove a clot, or angioplasty and stent placement to open a blocked artery and restore blood flow to the brain. The intervention dynamics for TBIs are limited as well and primarily focus on trying to reduce inflammation that happens after the injury occurs.
In response to this global need for more universal and broadly deliverable, frontline treatments, Algernon Pharmaceuticals Inc. (CSE: AGN | OTCQB: AGNPF | FSE: AGW0) (AGN Pharma), through its wholly-owned subsidiary Algernon NeuroScience (AGN Neuro), is working to repurpose psychedelic DMT from a mind-bending hallucinogenic, to a mind-mending sub-psychedelic therapeutic, that could potentially be administered to greater numbers of patients to help improve post-stroke and post-TBI outcomes for millions worldwide.
Building Confidently on Ifenprodil’s Success
With its Ifenprodil research program now sold to U.S. clinical-stage biopharmaceutical company Seyltx, Inc. for US$2 million and a 20% common share equity position, AGN Pharma has been able to move its DMT research program to lead status.
please visit the following link for the fulll story: BNN Bloomberg Story